Atara Biotherapeutics Faces Class Action for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ATRA?
Source: Globenewswire
- Lawsuit Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements: The complaint alleges that Atara made false and misleading statements regarding its ALLELE study, which suffered from manufacturing issues, making FDA approval for its tabelecleucel biologics license application unlikely, leading to investor losses when the truth emerged.
- Regulatory Risks: Atara faces heightened regulatory risks due to manufacturing deficiencies, and its public statements throughout the class period were deemed false and materially misleading, potentially eroding investor confidence and impacting stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, emphasizing its specialization in securities class action lawsuits aimed at helping investors recover losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.990
Low
18.00
Averages
21.50
High
25.00
Current: 4.990
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atara Biotherapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements: The complaint alleges that Atara made false and misleading statements regarding its ALLELE study, which suffered from manufacturing issues, making FDA approval for its tabelecleucel biologics license application unlikely, leading to investor losses when the truth emerged.
- Regulatory Risks: Atara faces heightened regulatory risks due to manufacturing deficiencies, and its public statements throughout the class period were deemed false and materially misleading, potentially eroding investor confidence and impacting stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, emphasizing its specialization in securities class action lawsuits aimed at helping investors recover losses.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky LLP has notified investors of Atara Biotherapeutics regarding a class action lawsuit due to alleged securities fraud occurring between May 20, 2024, and January 9, 2026, aimed at recovering losses for affected investors.
- Allegations Details: The complaint alleges that the defendants concealed manufacturing issues and deficiencies in the ALLELE study, making FDA approval of the tabelecleucel BLA unlikely, thereby overstating its regulatory prospects and potentially causing significant negative impacts on Atara's business and financial condition.
- Investor Rights: Affected Atara investors have until May 22, 2026, to request to be appointed as lead plaintiff to participate in any potential recovery, with no costs or obligations required to participate.
- Legal Team Strength: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its expertise in complex securities cases.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false or misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the FDA approval prospects for tabelecleucel and significantly impacted the company's financial condition.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record and expertise in this field.
- Investor Advisory: Investors are advised to carefully select qualified counsel, avoiding firms that lack experience, to ensure effective legal representation and support in the class action process.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which resulted in significant financial losses for investors and damaged the company's reputation and market confidence.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success rather than those acting merely as intermediaries, ensuring effective legal support and representation in the litigation.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, negatively impacting the company's financial condition.
- Choosing Legal Counsel: Rosen Law Firm emphasizes the importance of selecting experienced legal counsel to effectively protect investor rights, advising against firms that merely act as intermediaries without substantial litigation experience.
- Historical Performance: The firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities in securities litigation.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Class Action: Lufax Holding Ltd. is facing allegations for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, which undermines investor confidence due to misleading positive statements about the company's prospects.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. is accused of not disclosing manufacturing issues and clinical trial risks from May 20, 2024, to January 9, 2026, potentially overstating the likelihood of FDA approval for its product, which could significantly impact the company's financial condition.
- Coty Legal Issues: Coty Inc. is under scrutiny for failing to reveal underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, leading to misleading positive statements about its business operations and prospects, which may affect investor trust.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to reach out for legal rights discussions, emphasizing the firm's commitment to protecting investor interests.
See More
Atara Biotherapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements: The complaint alleges that Atara made false and misleading statements regarding its ALLELE study, which suffered from manufacturing issues, making FDA approval for its tabelecleucel biologics license application unlikely, leading to investor losses when the truth emerged.
- Regulatory Risks: Atara faces heightened regulatory risks due to manufacturing deficiencies, and its public statements throughout the class period were deemed false and materially misleading, potentially eroding investor confidence and impacting stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, emphasizing its specialization in securities class action lawsuits aimed at helping investors recover losses.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky LLP has notified investors of Atara Biotherapeutics regarding a class action lawsuit due to alleged securities fraud occurring between May 20, 2024, and January 9, 2026, aimed at recovering losses for affected investors.
- Allegations Details: The complaint alleges that the defendants concealed manufacturing issues and deficiencies in the ALLELE study, making FDA approval of the tabelecleucel BLA unlikely, thereby overstating its regulatory prospects and potentially causing significant negative impacts on Atara's business and financial condition.
- Investor Rights: Affected Atara investors have until May 22, 2026, to request to be appointed as lead plaintiff to participate in any potential recovery, with no costs or obligations required to participate.
- Legal Team Strength: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its expertise in complex securities cases.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false or misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the FDA approval prospects for tabelecleucel and significantly impacted the company's financial condition.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record and expertise in this field.
- Investor Advisory: Investors are advised to carefully select qualified counsel, avoiding firms that lack experience, to ensure effective legal representation and support in the class action process.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which resulted in significant financial losses for investors and damaged the company's reputation and market confidence.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success rather than those acting merely as intermediaries, ensuring effective legal support and representation in the litigation.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, negatively impacting the company's financial condition.
- Choosing Legal Counsel: Rosen Law Firm emphasizes the importance of selecting experienced legal counsel to effectively protect investor rights, advising against firms that merely act as intermediaries without substantial litigation experience.
- Historical Performance: The firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities in securities litigation.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Class Action: Lufax Holding Ltd. is facing allegations for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, which undermines investor confidence due to misleading positive statements about the company's prospects.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. is accused of not disclosing manufacturing issues and clinical trial risks from May 20, 2024, to January 9, 2026, potentially overstating the likelihood of FDA approval for its product, which could significantly impact the company's financial condition.
- Coty Legal Issues: Coty Inc. is under scrutiny for failing to reveal underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, leading to misleading positive statements about its business operations and prospects, which may affect investor trust.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to reach out for legal rights discussions, emphasizing the firm's commitment to protecting investor interests.
See More
